scholarly journals Short-Term Effects on Bone Turnover Markers of a Single High Dose of Oral Vitamin D3

2012 ◽  
Vol 97 (4) ◽  
pp. E622-E626 ◽  
Author(s):  
Maurizio Rossini ◽  
Davide Gatti ◽  
Ombretta Viapiana ◽  
Elena Fracassi ◽  
Luca Idolazzi ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Vitamin D3 ◽  
Bone Turnover Markers ◽  
High Dose ◽  
Oral Vitamin ◽  
Short Term ◽  
Single High Dose ◽  
Turnover Markers ◽  
Short Term Effects

Dose-Dependent Short-Term Effects of Single High Doses of Oral Vitamin D3 on Bone Turnover Markers

2012 ◽  
Vol 91 (6) ◽  
pp. 365-369 ◽  
Author(s):  
Maurizio Rossini ◽  
Silvano Adami ◽  
Ombretta Viapiana ◽  
Elena Fracassi ◽  
Luca Idolazzi ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Vitamin D3 ◽  
Bone Turnover Markers ◽  
Oral Vitamin ◽  
Short Term ◽  
Turnover Markers ◽  
High Doses ◽  
Dose Dependent ◽  
Short Term Effects

Short-Term Effects of TNF Inhibitors on Bone Turnover Markers and Bone Mineral Density in Rheumatoid Arthritis

2016 ◽  
Vol 98 (6) ◽  
pp. 580-585 ◽  
Author(s):  
Giovanni Orsolini ◽  
Giovanni Adami ◽  
Silvano Adami ◽  
Ombretta Viapiana ◽  
Luca Idolazzi ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Bone Mineral Density ◽  
Bone Turnover ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
Tnf Inhibitors ◽  
Mineral Density ◽  
Short Term ◽  
Turnover Markers ◽  
Short Term Effects

Single High-Dose Oral Vitamin D3 Therapy (Stoss)

2015 ◽  
Vol 61 (4) ◽  
pp. 411-414 ◽  
Author(s):  
Darren Shepherd ◽  
Andrew S. Day ◽  
Steven T. Leach ◽  
Robert Lopez ◽  
Rachel Messenger ◽  
...  
Keyword(s):  
Vitamin D3 ◽  
High Dose ◽  
Oral Vitamin ◽  
Single High Dose ◽  
Dose Oral

Twelve-weeks Oral Spray Vitamin D3 Supplementation Does Not Alter Bone Turnover Markers In Collegiate Gaelic Footballers

2017 ◽  
Vol 49 (5S) ◽  
pp. 105
Author(s):  
Sharon M. Madigan ◽  
Joshua Todd ◽  
Emeir McSorley ◽  
L. Kirsty Pourshahidi ◽  
Eamon Laird ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Vitamin D3 ◽  
Bone Turnover Markers ◽  
Vitamin D3 Supplementation ◽  
Turnover Markers

scholarly journals High-dose glucocorticoids increase serum levels of soluble IL-6 receptor α and its ratio to soluble gp130: an additional mechanism for early increased bone resorption

2006 ◽  
Vol 154 (5) ◽  
pp. 745-751 ◽  
Author(s):  
Andrea Dovio ◽  
Laura Perazzolo ◽  
Laura Saba ◽  
Angela Termine ◽  
Marco Capobianco ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Bone Resorption ◽  
Bone Turnover ◽  
Peripheral Blood ◽  
Bone Turnover Markers ◽  
Type I Collagen ◽  
Serum Levels ◽  
High Dose ◽  
Type I ◽  
Turnover Markers

Objective: Glucocorticoids (GCs) at pharmacological doses stimulate bone resorption. Mechanisms of this action are unclear. The osteoclastogenic cytokine interleukin (IL)-6 acts through an oligomeric receptor consisting of two subunits, gp80 (or IL-6 receptor α, IL-6Rα) and gp130; both exist in membrane and soluble forms. Soluble IL-6Rα (sIL-6Rα) enhances, while sgp130 inhibits IL-6 signalling. In vitro, GCs enhance many effects of IL-6 by up-regulation of IL-6Rα. The aim of the present study was to assess acute changes of IL-6 system in the peripheral blood of patients given high-dose GCs. Subjects and methods: Serum levels of IL-6, sIL-6Rα, sgp130 and bone turnover markers were assessed before and each day during treatment in 24 multiple sclerosis (MS) patients undergoing high-dose (prednisolone, 15 mg/kg per day), short-term (3 to 5 days) intravenous GC therapy for relapse at the Regional Multiple Sclerosis Centre. Results: An immediate and marked fall of osteocalcin and an early increase of C-terminal telopeptide of type I collagen were already noticed at day 2 (P < 0.001 and P < 0.02, respectively); both became more apparent in the subsequent days. IL-6 was always below or near the detection limit of our ELISA. sgp130 showed a slight increase. sIL-6Rα significantly increased, peaking at day 4 (P < 0.01). However, inter-individual variability of response was noticed. Four patients showed a slight decrease, while no change was observed in one patient and an increase was noticed in the remaining nineteen (maximum change ranging from +10% to +67% with respect to baseline). In these patients, a significant increase of sIL-6Rα/sgp130 ratio was apparent. No correlation was found between bone turnover markers and any measured component of the IL-6 system. Conclusions: sIL-6Rα and sIL-6Rα/sgp130 ratio are precociously increased in the peripheral blood of the vast majority of patients given high-dose, intravenous GCs. The increase of systemically available sIL-6Rα conceivably results in the enhancement of IL-6-dependent osteoclastogenesis. The role of such a mechanism in the bone loss observed in inflammatory and immune-mediated diseases (where abundancy of IL-6 in the bone microenvironment is expected) requires further investigation.

Sign in / Sign up

Export Citation Format

Share Document